XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.2
Organization and Summary of Significant Accounting Policies (Details Narrative)
 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 30, 2025
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
$ / shares
Nov. 16, 2024
USD ($)
Mar. 08, 2024
USD ($)
$ / shares
Jun. 30, 2025
USD ($)
$ / shares
Mar. 31, 2025
USD ($)
shares
Jun. 30, 2024
USD ($)
shares
Mar. 31, 2024
shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Mar. 20, 2025
USD ($)
Oct. 04, 2024
$ / shares
Product Information [Line Items]                          
Common stock, par value | $ / shares   $ 0.001     $ 0.001       $ 0.001   $ 0.001    
Conversion of convertible notes             $ 400,000            
Conversion of convertible notes, shares | shares                   223,463      
Short term investments   $ 6,900,000     $ 6,900,000       $ 6,900,000        
Capital raised from the Offering   5,300,000                      
Revenue from Contract with Customer, Excluding Assessed Tax         966,630   $ 385,896   1,360,202 $ 720,513      
Accounts receivable   715,317     715,317       715,317   $ 237,027    
Deferred tax assets   $ 18,800,000     $ 18,800,000       $ 18,800,000   $ 17,600,000    
Deferred tax assets valuation allowance coverage percent   100.00%     100.00%       100.00%   100.00%    
Anti-dilutie securities | shares           6,064,253   5,948,147   5,948,147      
Unvested Restricted Stock Units [Member]                          
Product Information [Line Items]                          
Anti-dilutie securities | shares           64,656   117,925 64,656 117,925      
Common Stock [Member]                          
Product Information [Line Items]                          
Anti-dilutie securities | shares           5,999,597   5,830.22 5,999,597 5,830.22      
Seven Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Concentration risk number of customers         8                
Seven Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
Product Information [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax                   $ 304,001      
Concentration risk percentage                   42.20%      
Ten Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Concentration risk number of customers             10            
Ten Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Concentration risk number of customers                 10        
Thirteen Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Concentration risk number of customers                   13      
Two Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax         $ 794,615                
Concentration risk percentage         58.40%   73.70%            
Four Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax             $ 284,594            
Four Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
Product Information [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax             $ 105,932            
Concentration risk percentage             27.50%            
Four Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
Product Information [Line Items]                          
Concentration risk percentage                     61.50%    
Accounts receivable                     $ 145,603    
Four Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax                 $ 1,101,653        
Concentration risk percentage                 80.90%        
Four Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax                 $ 658,005        
Concentration risk percentage                 92.00%        
Five Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax                   $ 506,379      
Concentration risk percentage                   70.30%      
Five Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax                     $ 158,416    
Three Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                          
Product Information [Line Items]                          
Concentration risk percentage                     66.90%    
Three Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
Product Information [Line Items]                          
Concentration risk percentage                 42.60%        
Accounts receivable   $ 304,548     $ 304,548       $ 304,548        
Three Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
Product Information [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax         $ 63,560       $ 111,893        
Concentration risk percentage         6.60%       8.20%        
Two CROs [Member] | Contract Research Organizations [Member] | Supplier Concentration Risk [Member]                          
Product Information [Line Items]                          
Concentration risk percentage         91.10%   96.50%   85.90% 90.20%      
Research services purchased         $ 880,020   $ 597,696   $ 1,363,447 $ 957,040      
Two CROs [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]                          
Product Information [Line Items]                          
Concentration risk percentage                 86.50%   58.90%    
Accounts payable   $ 638,908     $ 638,908       $ 638,908   $ 284,166    
Underwriting Agreement [Member]                          
Product Information [Line Items]                          
Shares of common stock | shares 6,052,000                        
Public offering price, per share | $ / shares $ 0.95                        
Proceeds from issuance initial public offering $ 5,300,000                        
Gates Foundation [Member]                          
Product Information [Line Items]                          
Proceeds from grants     $ 3,092,136                    
Revenue from Contract with Customer, Excluding Assessed Tax           $ 361,759     538,107        
CEPI [Member]                          
Product Information [Line Items]                          
Grant receivable                       $ 2,400,000  
Revenue from Contract with Customer, Excluding Assessed Tax           $ 141,422     $ 175,545        
CEPI [Member] | Fondazione Biotecnopolo Di Siena Fbs [Member]                          
Product Information [Line Items]                          
Grant receivable                       $ 4,500,000  
Common Stock [Member]                          
Product Information [Line Items]                          
Conversion of convertible notes             $ 223       $ 910,000    
Conversion of convertible notes, shares | shares             223,463       556,623    
Senior Secured Convertible Promissory Notes [Member]                          
Product Information [Line Items]                          
Convertible note principal       $ 6,000,000.0                  
Interest rate       8.00%                  
Proceeds from sale of convertible notes       $ 5,824,326                  
Common stock, par value | $ / shares       $ 0.001                  
Debt instrument convertible conversion price | $ / shares                         $ 1.40